Gainers
- TFF Pharmaceuticals TFFP stock moved upwards by 27.9% to $2.63 during Friday's pre-market session. The market value of their outstanding shares is at $9.1 million.
- Centene CNC shares increased by 12.62% to $69.4. The market value of their outstanding shares is at $36.5 billion. As per the press release, Q3 earnings came out today.
- Nexalin Technology NXL shares rose 9.31% to $2.35. The company's market cap stands at $24.8 million.
- Citius Oncology CTOR stock rose 8.76% to $1.31. The company's market cap stands at $93.4 million.
- Actinium Pharma ATNM stock moved upwards by 8.33% to $1.82. The company's market cap stands at $56.7 million.
- BioVie BIVI stock increased by 8.11% to $2.93. The company's market cap stands at $23.3 million.
Losers
- Monopar Therapeutics MNPR shares declined by 23.9% to $24.85 during Friday's pre-market session. The market value of their outstanding shares is at $87.4 million.
- Quince Therapeutics QNCX stock fell 15.97% to $1.0. The company's market cap stands at $43.2 million.
- Bionomics BNOX stock decreased by 14.89% to $0.31. The company's market cap stands at $4.0 million.
- Hepion Pharmaceuticals HEPA shares declined by 11.01% to $0.65. The market value of their outstanding shares is at $3.7 million.
- Dogwood Therapeutics DWTX stock declined by 10.11% to $4.27. The company's market cap stands at $5.6 million.
- Passage Bio PASG shares declined by 9.91% to $0.58. The company's market cap stands at $35.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BIVIBioVie Inc
$1.95-6.25%
BNOXBionomics Ltd
$0.2415-3.44%
CNCCentene Corp
$59.58-0.22%
CTORCitius Oncology Inc
$0.9900-6.60%
DWTXDogwood Therapeutics Inc
$2.456.06%
HEPAHepion Pharmaceuticals Inc
$0.5035-4.82%
MNPRMonopar Therapeutics Inc
$25.828.53%
NXLNexalin Technology Inc
$2.75-10.1%
PASGPassage Bio Inc
$0.65830.66%
QNCXQuince Therapeutics Inc
$1.855.11%
TFFPTFF Pharmaceuticals Inc
$0.1380112.3%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in